Name | N-[(3S,4S)-6-acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]-3-chloro-4-fluorobenzamide |
---|---|
Synonyms |
Tonabersat
Tonabersat [BAN,INN] UNII-2XD9773ZMN USL-260 |
Description | Tonabersat is a gap-junction modulator. |
---|---|
Related Catalog | |
Target |
Gap-junction[1] |
In Vitro | Tonabersat, a novel benzopyran derivative, inhibits cortical spreading depression (CSD) and therefore might be able to inhibit the early migraine mechanisms[1]. |
In Vivo | Treatment with either Tonabersat (10 mg/kg) or Meclofenamate (20 mg/kg) as single agents significantly inhibit progression of metastatic lesions. Addition of carboplatin to either agent profoundly inhibits brain metastasis[2]. |
Animal Admin | Mice[2] Athymic NCR nu/nu mice, Cr:NIH bg-nu-xid mice, B6129SF1/J, C57BL/6J-Tmem173gt/J 'golden ticket', and C57/Bl/6J mice are used at 5-6 weeks of age. For inducible knockdown experiments, mice are given doxycycline hyclate in the drinking water (2 mg/mL) and the diet 14 days after injection of cancer cells. For drug treatment experiments, mice are intraperitoneally injected with Carboplatin (5 mg/kg per 5 days), Tonabersat (MedChem Express) (10 mg/kg per day), or meclofenamic acid sodium salt (20 mg/kg per day). Vehicle (10% DMSO in polyethylene glycol 400) is used in control mice. Quantification of tumour burden is by Bio-luminescent imaging (BLI), performed using an IVIS Spectrum Xenogen instrument and analysed using Living Image software v.2.50. |
References |
Density | 1.38g/cm3 |
---|---|
Boiling Point | 554.5ºC at 760 mmHg |
Molecular Formula | C20H19ClFNO4 |
Molecular Weight | 391.82100 |
Flash Point | 289.2ºC |
Exact Mass | 391.09900 |
PSA | 75.63000 |
LogP | 4.07560 |
Vapour Pressure | 3.94E-13mmHg at 25°C |
Index of Refraction | 1.612 |
Storage condition | 2-8℃ |
Symbol |
GHS07, GHS09 |
---|---|
Signal Word | Warning |
Hazard Statements | H315-H319-H400 |
Precautionary Statements | P273-P280-P305 + P351 + P338-P337 + P313-P391 |
RIDADR | UN 3077 9 / PGIII |